Boston, 14 - 15 September 2027
Schedule
Create your personal agenda –check the favourite icon
Sep 149:00
Conference pass
Opening Keynote Panel: PBM Reform, Transparency, and the Future of the Purchaser-Payer Relationship
Keynotes
- Navigating the Shifting Dynamics of the PBM-Payer Relationship: Strategies for a New Era of Transparency and Value
- Have the recent major PBM reforms been effective in increasing patient access?
- In a world where the government dictates prices and posts them online, how will the role of payer’s change?
- Has the landscape settled yet, what else can we expect to see in terms of PBM reform in 2028?
- The effects of 340B reform on PBM-run contract pharmacies and manufacturers GtN
- How much are direct-to-patient and cash price models affecting the current landscape?
Moderator: John O'Brien, President and CEO, National Pharmaceutical Council
Rujul Desai, Senior Counsellor, Centers for Medicare & Medicaid Services
Shawn Gremminger, CEO, National Alliance of Healthcare Purchaser Coalitions
AJ Loiacono, CEO, Judi Health
Sep 1410:00
Conference pass
MFN and US Pricing Policy: Preparing for the Upcoming US Legislative Shifts and Their Impact on Global and Long-Term Pricing Strategy
Keynotes
- The global impact of MFN & International Reference Pricing
- Future-proofing launch pricing across the US and Europe in the light of US pricing reforms
- What can the US learn from non-US markets in terms of drug valuation and pricing strategy?
Moderator: Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine
Robert Popovian, Senior Visiting Fellow, Pioneer Institute
Sep 1415:10
Conference pass
Global Interplay Between US And Ex-US Market Dynamics
Patient Access and Services
- Aligning US and European regulatory requirements with HTA
- What are the first outcomes of the EU JCA
- How do we ensure access to innovative therapies on both sides of the Atlantic
- What is the EU doing to facilitate access in innovative medicines
- Implications of US pricing on EU markets
- General implications of International Reference Pricing (US and Ex-US)
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Sep 1415:10
Conference pass
Reforming 340B: What Can Be Done to Regain Program Integrity?
Policy and Reform
- Current status of the 340B rebate pilot (beginning Jan 2027)
- How do we improve transparency into the ways hospitals are using 340B revenue?
- How can we ensure patients are feeling the benefit?
- The role of manufacturers and pharmacies in ensuring program integrity is maintained? (Avoiding duplicate discounts, increasing transparency in claims data submissions)
- Are there any supply chain implications?
Moderator: Brian Reid, Principal, Reid Strategic
Katy Lees, Director, 340B Policy and Business Strategy, University of Rochester Medical Center
Paul Schiferl, 340B Consultant, Citizens Medical Center
Sep 1415:10
Conference pass
Next Generation Launch Sequencing Strategies: How to Succeed in an Increasingly Volatile Global Climate
Market Access and Commericalization
- Current approaches to secure launch success in a post-MFN World
- Are ex-U.S. health systems and HTA bodies (like NICE or G-BA) changing their negotiation tactics to ensure pharma companies still launch in their country?
- Shifting from US>EU>UK launch sequences to a more flexible launch sequence
- Can we anticipate policy and pricing shifts ahead of launches?
- The opportunities for AI enabled launch strategies
Kevyn Adler, Senior Director, Market Access Product & Pipeline Strategy, Regeneron
Sep 1415:10
Conference pass
Bridging the US Payer Trust with Robust Real-World Evidence
HEOR and RWE
- Payers' Perspective on RWE in the US
- How can we align manufacturer evidence with PBM requirements, can the same data also influence CMS and state-level decisions?
- How do we establish standardized RWE benchmarks to fairly and accurately cap prices using up to date HTA data?
- How can manufacturers prove clinical ROI within the standard 3-to-5-year U.S. payer population turnover window, rather than relying on lifetime models?
Charles Makin, Head of US Real World Evidence & Epidemiology, Boehringer Ingelheim
Daniel Ollendorf, Chief Scientific Officer and Director of Health Technology Assessment Methods and Engagement, ICER
Kimberly Lenz, Chief Pharmacy Officer, MassHealth
Patricia Dorling, Senior Director, HEOR, Gene Therapy, Insmed
Sep 1415:10
Conference pass
Affording The Unaffordable: Solutions For Financing High-Cost Curative Therapies
Specialty Pharmacy
Current landscape of pricing and access in Rare Disease/ C&G / CAR-T therapies (in 2027)How do we balance the cost of curative next generation therapies against overall system affordability?Is there a way to sustainably accommodate the rise in high-cost therapies without causing collapse of major payers such as Medicaid?
Susan Dentzer, President & CEO, America's Physician Groups
Melanie Lendnal, Senior Vice President, Policy & Advocacy, The ALS Association
Sep 1415:10
Conference pass
AI and Market Access: Utilizing Clinical and Economic Evidence In Reimbursement Discussions
Artificial Intelligence
- How is AI going to be used to reduce costs?
- Strategic advantages of AI-driven Pricing, Reimbursement, and Market Access decision making
- What do payers require before accepting AI-assisted economic models and real-world evidence?
- Outlook for 2028: Progressing the use for large sale adoption
- Overcoming issues with data quality and availability
- What/ where is the role of human oversight in evidence generation and decision making?
Moderator: Daisuke Goto, Director, Medical Affairs and Outcomes Research, Organon
Sven Klijn, Director, HEOR Evidence Acceleration & Innovation, Bristol Myers Squibb
Jag Chhatwal, Director, Center for Health Technology Assessment, Harvard Medical School
Create your personal agenda –check the favourite icon
Sep 159:00
Conference pass
Keynote Opening Panel: A Vision for Transparent, Value-Aligned Launch Pricing in 2027 and Beyond
Keynotes
- How have launch prices evolved since the IRA and what does a fair launch price look’s like in the 2027 landscape?
- The importance of lifecycle management, pre and post launch
- Navigating high-value and or high-volume therapies in a fragmented system
- What is the future of drug pricing? Is every main decision driving towards net channel pricing?
Moderator: Peter Neumann, Professor, Tufts Medical Center
Ellie Adair, Chief Operating Officer, ICER
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Charles Makin, Head of US Real World Evidence & Epidemiology, Boehringer Ingelheim
Sean Dickson, Senior Vice President, Pharmaceutical Policy and Strategy, AHIP
Sep 1510:00
Conference pass
The Modernization of Specialty Pharmacy: How Have the Roles of Key Stakeholders Shifted in the Access Journey?
Keynotes
- How does the influx of high cost, high value medications blur the lines between retail and specialty pharmacy (GLP-1s, SGLT2s)
- How do you ensure there is enough value forallkey stakeholders to participate in a product's SP strategy, so the patient actually gets the drug?
- What actions need to be taken by all stakeholders in complex case patients?
- What is the role of Specialty Pharmacy in delivering payer goals?
- What is the future of specialty pharmacy?
William Shrank, CEO and Co- Founder, Aradigm
Aleata Postell, Senior Vice President Pharmacy Business Development, Humana
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Annette Powers, Senior Vice President, Global Access & Value and Public Policy (GAVP), Astellas
Sep 1515:10
Conference pass
Two years on from the First Wave of MFP-Priced Drugs: What Have We Learnt?
Patient Access and Services
- Learnings from first two waves of negotiations and roll-out of MFP-priced drugs on the market
- Part B injectables negotiations
- Impact on supply chain to execute MFP
- Gross to net challenges and the impact on GPOs and Pharmacies
Katheryne Richardson, Chief Strategy Officer, Second Sight Solutions
Jocelyn Ulrich, Vice President, PhRMA
Sep 1515:10
Conference pass
Shielding Rare Disease & Orphan Drugs from MFN and Global Price Compression
Policy and Reform
- How MFN is reshaping global pricing and launch strategy for orphan drugs?
- US and Ex-US Launch implications
- Practical considerations for managing pricing risk while protecting patient access
- Protecting the Orphan drug market from policies designed for high volume drugs
Speakers to be announced
Sheela Upadhyaya, Rare Disease Consultant, Rarely Ordinary
Sep 1515:10
Conference pass
Rethinking Trial Design for Market Access: Aligning R&D With HTA And IRA Demands For Strong Post Market Outcomes
HEOR and RWE
- How can Manufacturers leverage RWE to build and defend product value to HTAs and before early IRA statutory negotiation triggers hit?
- Potential strategies for integrating Comparative effectiveness metrics in phase II/III trial design
- Can we adapt trial design to account for real world care settings (e.g.CAR-T therapies)
- Can we use prospective RWE and value-based contracts to satisfy to HTA data requirements, FDA Accelerated Approvals and payer demands for long-term comparative evidence?
Alan Balch, Chief Executive Officer, Patient Advocate Foundation
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Sep 1515:10
Conference pass
Delivering Patient Centric Outcomes At Scale: Solving The Specialty Access Crisis
Specialty Pharmacy
How the role of specialty pharmacy is shifting as more drugs shift to an outpatient setting (CAR-T, C&G, GLP-1s)How Payers and manufacturers are utilizing PROs and RWE from specialty pharmacists in payer negotiations and drug developmentThe value in integrating specialty pharmacy data with community-based resources to address SDoH concernsDigital and AI integration into specialty pharmacy to personalize the patient journey and reduce the Total Cost of Care
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Sep 1515:10
Conference pass
The AI Arms Race: Navigating The Automation Of Processes Across All Stakeholders In The Healthcare Industry
Artificial Intelligence
- Why has automated friction between provider and payer AI systems driven record healthcare inflation while patient outcomes stayed flat?
- How can we responsibly operationalize AI in industry workflows to drive faster patient access and lower costs
- Can we effectively regulate the use of agentic AI in billing without compromising efficacy, care or eroding patient trust?
Siguroli Teitsson, Director, GHEOR Economic & Predictive Modeling, Bristol Myers Squibb
last published: 08/Sep/26 08:20 GMT
Get Involved
Speaking Opportunities
Charlie Humphrey
Charlie.humphrey@terrapinn.com
Marketing Opportunities
Hidy Lee
hidy.lee@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events